

Overview

Useful For

Aids in diagnosing central nervous system West Nile virus infections during the acute phase

Method Name

Only orderable as part of a profile. For more information see WNC / West Nile Virus Antibody, IgG and IgM, Spinal Fluid.

Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available

No

Specimen

Specimen Type

CSF

Specimen Required

Only orderable as part of a profile. For more information see WNC / West Nile Virus Antibody, IgG and IgM, Spinal Fluid.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Sterile vial

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Submit specimen from collection vial 2, 3, or 4

Specimen Minimum Volume

0.8 mL

Reject Due To

Gross hemolysis	Reject
-----------------	--------

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
CSF	Refrigerated (preferred)	7 days	
	Frozen	30 days	

Clinical & Interpretive**Clinical Information**

West Nile virus (WNV) is a mosquito-borne flavivirus (single-stranded RNA) that primarily infects birds and can also infect humans and horses. WNV was first isolated in 1937 from an infected person in the West Nile district of Uganda. Until the viral infection was recognized in 1999 in birds in New York City, WNV was found only in the Eastern Hemisphere, with wide distribution in Africa, Asia, the Middle East, and Europe.(1-3) Most recently, in 2012, a total of 5674 cases of WNV were reported to the Centers for Disease Control and Prevention, among which 2873 (51%) were classified as neuroinvasive disease (eg, meningitis or encephalitis) and 286 (5%) cases resulted in death.(2)

Most people who are infected with WNV will not develop clinical signs of illness. It is estimated that about 20% of those who become infected will develop West Nile fever with mild symptoms, including fever, headache, myalgia, and occasionally a skin rash on the trunk of the body. Case fatality rates among patients hospitalized during recent outbreaks have ranged from 4% to 14%. Advanced age is the most important risk factor for death, and patients older than 70 years of age are at particularly high risk.(1)

Laboratory diagnosis is best achieved by demonstration of specific IgG and IgM class antibodies in serum specimens. Polymerase chain reaction (PCR) (WNCSE / West Nile Virus, RNA, PCR, Molecular Detection, Spinal Fluid) can detect WNV RNA in specimens from patients with recent WNV infection (ie, 3-5 days following infection) when specific antibodies to the virus are not yet present. However, the likelihood of detection is relatively low as the sensitivity of PCR detection is approximately 55% in spinal fluid and approximately 10% in blood from patients with known WNV infection.

Reference Values

Only orderable as part of a profile. For more information see WNC / West Nile Virus Antibody, IgG and IgM, Spinal Fluid.

IgM: Negative

Reference values apply to all ages.

Interpretation

A positive result is consistent with the acute phase of West Nile virus (WNV) meningitis or encephalitis. In the very early stages of acute WNV infection, IgM may be detectable in spinal fluid before it becomes detectable in serum.

A negative result may indicate absence of disease. However, specimens collected too early in the acute phase may be negative for IgM-class antibodies to WNV. If WNV central nervous system infection is suspected, a second specimen should be collected in 1 to 2 weeks and tested.

Cautions

Test results should be used in conjunction with clinical evaluation, exposure history and other available diagnostic procedures.

The significance of negative test results in immunosuppressed patients is uncertain.

False-negative results due to competition by high levels of IgG, while theoretically possible, have not been observed.

False-positive results may occur in patients infected with other flaviviruses, including dengue virus, St. Louis virus, and Zika virus and in persons previously infected with West Nile virus (WNV).

Because closely related arboviruses exhibit serologic cross-reactivity, it sometimes may be epidemiologically important to attempt to pinpoint the infecting virus by conducting plaque reduction neutralization tests using an appropriate battery of closely related viruses. Such testing is available through the Centers for Disease Control and Prevention and select public health laboratories.

WNV antibody results for spinal fluid (CSF) should be interpreted with caution. Complicating factors include low antibody levels found in CSF, passive transfer of antibody from blood, and contamination via a traumatic lumbar puncture.

Clinical Reference

1. Petersen LR, Marfin AA. West Nile Virus: a primer for the clinician. *Ann Intern Med.* 2002;137:173-179
2. Centers for Disease Control and Prevention (CDC). West Nile virus and other arboviral diseases--United States, 2012. *MMWR Morb Mortal Wkly Rep.* 2013;62(25):513-517
3. Brinton MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. *Ann Rev Microbiol.* 2002;56:371-402
4. Habarugira G, Suen WW, Hobson-Peters J, Hall RA, Bielefeldt-Ohmann H. West Nile virus: an update on pathobiology, epidemiology, diagnostics, control and "one health" implications. *Pathogens.* 2020;9(7):589

Performance

Method Description

Polystyrene microwells are coated with the antihuman antibody specific for IgM (μ -chain). Diluted serum specimens and controls are incubated in the wells. The IgM present in the specimen binds to the antihuman antibody (IgM specific) in the wells. Nonspecific reactants are removed by washing. West Nile virus (WNV) antigen is then added to the wells and incubated. If anti-WNV IgM is present in the specimen, the WNV antigen binds to the anti-WNV in the well. Unbound WNV antigen is then removed by washing the well. Mouse anti-flavivirus conjugated with horseradish peroxidase (HRPO) is then added to the wells and incubated. If WNV antigen has been retained in the well by the anti-flavivirus in the specimen, the mouse anti-flavivirus: HRPO binds to WNV antigen in the wells. Excess conjugate is removed by washing. Enzyme substrate and chromogen are added, and the color is allowed to develop. After adding the Stop reagent, the resultant color change is quantified by a spectrophotometric reading of optical density (OD) that is directly proportional to the amount of antigen-specific IgM present in the specimen. Specimen OD readings are compared with reference cutoff OD readings to determine results. (Package insert: West Nile Virus IgM Capture DxSelect. Focus Diagnostics; 12/16/2022)

PDF Report

No

Day(s) Performed

Monday, Wednesday, Friday

Report Available

Same day/1 day

Specimen Retention Time

14 days

Performing Laboratory Location

Jacksonville

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86788

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
WNMC	West Nile Virus Ab, IgM, CSF	29569-1

Result ID	Test Result Name	Result LOINC® Value
WNMC	West Nile Virus Ab, IgM, CSF	29569-1